



THE WHITE HOUSE
WASHINGTON

COVID-19 Press Briefing

August 12, 2021



Daily Change in COVID-19 Cases, US

January 22, 2020 – August 10, 2021

TOTAL Cases Reported Since 1/22/20

36,125,176

NEW Cases Reported to CDC on 8/10/21

132,384

Change in 7-Day Case Average


+24.3%

Current 7-Day Case Average (8/4/21 - 8/10/21)

113,357

Prior 7-Day Case Average (7/28/21 - 8/3/21)

91,192



New Admissions of Patients with Confirmed COVID-19, US

August 1, 2020 – August 9, 2021

Patients Currently Hospitalized with COVID on 8/9/21

66,186

New Admissions on 8/9/21

9,970

Peak in New Admissions (1/5/21)

17,963

Change in 7-Day Average of New Admissions


+31.3%

Current 7-Day Average of New Admissions (8/3/21 - 8/9/21)

9,712

Prior 7-Day Average of New Admissions (7/27/21 - 8/2/21)

7,397



Daily Change in COVID-19 Deaths, US

January 22, 2020 – August 10, 2021

TOTAL Deaths Reported Since 1/22/2020

616,459

NEW Deaths Reported to CDC on 8/10/21

664

Change in 7-Day Death Average

+22.2%

Current 7-Day Death Average (8/4/21 - 8/10/21)


452

Prior 7-Day Death Average (7/28/21 - 8/3/21)

370

Forecasted Total Deaths by 9/04/21

630,000 to 662,000



The SARS-CoV-2 B.1.617.2 (Delta) Variant Has Been Detected in at Least 117 Countries Since First Found in June 2020



Source: Outbreak.info



Delta Variant

- **Transmissibility** greater than Alpha variant – 2x greater at least
- **Viral loads** up to 1000x greater than Alpha variant



At Least 5 Vaccines Have Some Proof of Protection Against the SARS-CoV-2 Delta Variant

	Lab Studies	Clinical Effectiveness
Pfizer/BioNTech	✓	✓
Moderna	✓	✓
Johnson & Johnson	✓	✓
AstraZeneca	✓	✓
Bharat Biotech	✓	✓

Adapted from E Topol, MD.





The
New England
Journal of Medicine

Established in 1812 as THE NEW ENGLAND JOURNAL OF MEDICINE AND SURGERY

Published online July 14, 2021

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination

DH Barouch, H Schuitemaker et al.

- **Johnson & Johnson vaccine elicited durable antibody and cellular immune responses against Delta variant with minimal decreases for at least 8 months after immunization**
- **Expansion of neutralizing antibody breadth and improved coverage of variants over time**




J&J Vaccine Highly Effective Against Delta Variant in South African Trial

- **Sisonke study, n=477,234 healthcare workers**
- **91-96% protection against death**
- **71% protection against hospitalization**
- **Durability of immune responses out to 8 months**
- **First real-world data to show effectiveness of J&J vaccine, from a challenging epidemiological setting**



Breakthrough Infections Mostly Mild in Sisonke Study



Source: G. Gray presentation, <https://bit.ly/2VCC0d1>, 8/6/2021.



THE WHITE HOUSE
WASHINGTON

WH.GOV